Studies related to Cognitive Decline and Alpha-GPC

Cognitive Improvement In Mild To Moderate Alzheimer's Dementia After Treatment With The Acetylcholine Precursor Choline Alfoscerate: A Multicenter, Double-blind, Randomized, Placebo-controlled Trial

Effect Decrease
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 261
Sex Both Genders
Age Range 65+
Body Types Average, Underweight
Notes for this study:
Supplementation of Alpha-GPC at 400mg thrice daily (1,200mg daily) for 180 days in persons with mild to moderate Alzheimer's disease was able to improve symptoms as assessed by a multitude of rating scales including ADAS, MMSE, CDI, and GDS.